#USA #Philadelphia #Verismo Therapeutics #Mesothelioma #KIR-CAR

Verismo Therapeutics to Present at iMig 2025

Verismo Therapeutics, a pioneering clinical-stage company specializing in CAR T therapies, has recently announced its participation and sponsorship of the International Mesothelioma Interest Group (iMig) 2025 Conference. This event is crucial for discussing advancements in mesothelioma treatments, a rare and aggressive cancer afflicting thousands worldwide. Verismo will spotlight its lead pipeline product, SynKIR™-110, particularly its ongoing Phase 1 clinical trial known as STAR-101.

Understanding Mesothelioma

Mesothelioma is notorious for being challenging to treat, with over 2,500 new cases reported each year in the United States alone, and around 30,000 cases globally. Despite the emergence of novel therapies, the prognosis for patients suffering from this disease remains dire, often leaving them with limited treatment options. Mesothelioma is characterized by the overexpression of mesothelin, a protein that SynKIR™-110 specifically targets, allowing it to directly attack cancer cells.

In 2022 and 2023, the Food and Drug Administration (FDA) granted Orphan Drug and Fast Track Designations to SynKIR™-110, recognizing its potential in addressing this critical health challenge.

Insights from Experts

Dr. Daniel Sterman, a prominent figure in pulmonary medicine at NYU Grossman School of Medicine, emphasized the historical neglect in treatment innovations for mesothelioma. "With STAR-101 and our sponsorship at iMig, Verismo is committed to pushing the science forward, highlighting the urgent medical needs within the mesothelioma community," he remarked. Dr. Sterman is also the Medical Monitor for the STAR-101 study, further advocating for more robust research in this area.

Details of STAR-101 Clinical Trial

STAR-101 is a multicenter, open-label Phase 1 clinical trial designed to assess the safety, feasibility, and preliminary efficacy of SynKIR™-110 in patients with advanced mesothelin-expressing tumors. This study marks a significant step as it introduces Verismo's innovative multi-chain KIR-CAR platform to solid tumors for the first time.

Presentation Highlights

• - Title of Presentation: SynKIR-CAR T Cell Advanced Research (STAR)-101 Phase 1 Clinical Trial for Patients with Advanced Mesothelin-expressing Mesothelioma, Ovarian Cancer, or Cholangiocarcinoma
• - Session: Novel Combinations and Applications of Immunotherapy; Salon E
• - Date/Time: Monday, October 27, 2025, 2:30 - 2:45 PM
• - Presenter: Jun Xu, Ph.D., Executive Director of Translational Science at Verismo Therapeutics

Verismo's Commitment to Innovation

Verismo Therapeutics aims to set a new standard in cancer treatment with its unique KIR-CAR platform technology. The company is the only entity developing this platform, which integrates a modified NK cell-derived receptor with DAP12 pairing, targeting the improvement of T cell durability and reducing exhaustion in tumor combat. This cutting-edge approach not only strives to enhance efficacy against even the most resilient tumors but also addresses critical medical needs in advanced solid tumors and other malignancies associated with B cell disorders.

As a part of their commitment, Verismo's sponsorship of iMig 2025 exemplifies their focus on supporting patients, clinicians, and advocates committed to advancing mesothelioma care globally. The opportunity to discuss STAR-101 and its potential impact marks another pivotal moment for Verismo as it seeks to transform the treatment landscape for this challenging disease.

A Forward-Looking Perspective

Verismo Therapeutics continues to stay optimistic about the outcomes of its clinical trials, projecting that its innovative approaches will pave the way for new, effective therapies. By eliminating traditional barriers faced in treating mesothelioma, Verismo strives to enhance the lives of patients grappling with this formidable illness and to shift the paradigm towards more hopeful outcomes in cancer treatment.

For more updates and detailed information, please visit Verismo Therapeutics.